Proficio Capital Partners LLC purchased a new position in QuidelOrtho Co. (NASDAQ:QDEL - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 19,557 shares of the company's stock, valued at approximately $871,000.
Other large investors also recently modified their holdings of the company. Blue Trust Inc. grew its position in QuidelOrtho by 188.0% in the 4th quarter. Blue Trust Inc. now owns 1,293 shares of the company's stock valued at $58,000 after buying an additional 844 shares in the last quarter. Spire Wealth Management acquired a new stake in shares of QuidelOrtho in the 4th quarter worth approximately $74,000. KBC Group NV boosted its holdings in shares of QuidelOrtho by 122.9% in the fourth quarter. KBC Group NV now owns 3,437 shares of the company's stock valued at $153,000 after acquiring an additional 1,895 shares in the last quarter. Captrust Financial Advisors acquired a new position in shares of QuidelOrtho during the third quarter valued at approximately $238,000. Finally, CIBC Asset Management Inc bought a new stake in QuidelOrtho during the third quarter worth approximately $262,000. 99.00% of the stock is owned by institutional investors and hedge funds.
QuidelOrtho Trading Down 3.2 %
QDEL traded down $1.16 during trading on Tuesday, reaching $35.35. The company had a trading volume of 808,434 shares, compared to its average volume of 933,361. The firm's 50-day simple moving average is $40.62 and its 200 day simple moving average is $41.65. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.69 and a current ratio of 1.22. The company has a market cap of $2.38 billion, a price-to-earnings ratio of -1.17 and a beta of 0.10. QuidelOrtho Co. has a 12-month low of $29.74 and a 12-month high of $49.45.
QuidelOrtho (NASDAQ:QDEL - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.07 by ($0.44). QuidelOrtho had a negative net margin of 72.84% and a positive return on equity of 3.78%. Equities research analysts anticipate that QuidelOrtho Co. will post 2.3 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the company. UBS Group increased their price target on QuidelOrtho from $43.00 to $45.00 and gave the company a "neutral" rating in a research note on Thursday, February 13th. StockNews.com lowered QuidelOrtho from a "buy" rating to a "hold" rating in a report on Saturday, February 15th. Jefferies Financial Group initiated coverage on shares of QuidelOrtho in a report on Tuesday, December 10th. They issued a "hold" rating and a $43.00 price target for the company. Royal Bank of Canada lowered their price objective on shares of QuidelOrtho from $64.00 to $61.00 and set an "outperform" rating on the stock in a research note on Thursday, February 13th. Finally, Citigroup upgraded shares of QuidelOrtho from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $44.00 to $50.00 in a report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $51.20.
Check Out Our Latest Stock Report on QuidelOrtho
About QuidelOrtho
(
Free Report)
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
See Also
Before you consider QuidelOrtho, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and QuidelOrtho wasn't on the list.
While QuidelOrtho currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
